Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 953,759
  • Shares Outstanding, K 41,740
  • Annual Sales, $ 6,050 K
  • Annual Income, $ -97,180 K
  • 36-Month Beta 4.78
  • Price/Sales 159.69
  • Price/Cash Flow 0.00
  • Price/Book 5.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.00 +26.94%
on 08/23/17
24.50 -6.73%
on 09/21/17
+4.44 (+24.12%)
since 08/22/17
3-Month
15.28 +49.54%
on 07/27/17
24.50 -6.73%
on 09/21/17
+5.31 (+30.27%)
since 06/22/17
52-Week
12.43 +83.83%
on 11/03/16
29.20 -21.75%
on 03/14/17
+8.05 (+54.39%)
since 09/22/16

Most Recent Stories

More News
Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health

Flagship Pioneering, a fully-integrated life science innovation enterprise, today unveiled Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries that unlock the power...

SYRS : 14.93 (-3.43%)
AGIO : 66.07 (-1.56%)
MCRB : 16.75 (-0.12%)
EDIT : 22.85 (-1.34%)
Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte

If you want a Stock Review on CLVS, DERM, EDIT, or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 14, 2017, US markets...

DERM : 26.24 (-1.20%)
CLVS : 78.56 (+2.09%)
ECYT : 1.39 (+0.72%)
EDIT : 22.85 (-1.34%)
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10). LCA10 is...

EDIT : 22.85 (-1.34%)
Watching the Weather

Watching the Weather

PTCT : 18.52 (-7.63%)
EDIT : 22.85 (-1.34%)
RCL : 115.29 (-0.77%)
NOMD : 14.94 (-0.47%)
Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the Morgan Stanley 15 Annual Global Healthcare Conference on...

MS : 48.22 (-0.08%)
EDIT : 22.85 (-1.34%)
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

EDIT : 22.85 (-1.34%)
ALXN : 142.82 (-0.07%)
BUYINS.NET: EDIT SqueezeTrigger Price is $20.72. There is $117,581,437 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Editas Medicine Inc. (NASDAQ:EDIT) in real time and just received an alert that EDIT is crossing above its primary SqueezeTrigger Price, the price that a short...

EDIT : 22.85 (-1.34%)
Editas Medicine Announces Second Quarter 2017 Results and Update

Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials

EDIT : 22.85 (-1.34%)
J.P. Morgan Vice Chairman Stephen Berenson Joins Flagship Pioneering

Flagship Pioneering, a fully-integrated life science innovation enterprise, today announced that Stephen Berenson has joined the firm as executive partner. The former vice chairman of investment banking...

SYRS : 14.93 (-3.43%)
AGIO : 66.07 (-1.56%)
MCRB : 16.75 (-0.12%)
JPM : 94.83 (-0.21%)
EDIT : 22.85 (-1.34%)
Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / Editas Medicine's shares plunged yesterday after a published paper in the scientific journal Nature Methods revealed that the genome editing tool CRISPR/Cas9,...

EDIT : 22.85 (-1.34%)
VRX : 14.01 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Support & Resistance

2nd Resistance Point 23.77
1st Resistance Point 23.31
Last Price 22.85
1st Support Level 22.47
2nd Support Level 22.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.